Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indocyanine green + p28 (ICG-p28) is an intraoperative near-infrared (NIR) fluorescence imaging probe designed for the real-time identification of tumor margins during surgery. It consists of the fluorescent dye indocyanine green (ICG) conjugated to p28, a 28-amino acid cell-penetrating peptide derived from the bacterial protein azurin. The p28 peptide serves as a tumor-targeting moiety that preferentially enters cancer cells and binds to the DNA-binding domain of the p53 tumor suppressor protein, though its primary role in this conjugate is to facilitate selective accumulation of ICG within malignant tissues. This targeted approach is intended to improve the accuracy of breast-conserving surgery for ductal carcinoma in situ (DCIS) and invasive breast cancer by clearly delineating tumor boundaries, thereby reducing positive margin rates and the necessity for follow-up re-excision procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indocyanine green + p28.